

1 **Identification of tRNA-derived small RNAs and their potential**
2 **roles in the hippocampus of nicotine exposure rats**

3 Jiali Shao^{1†}, YanXia Fei¹, ChenSu¹, Wangyuan Zou², JinFeng Yang^{1*}

4 ¹Department of Anesthesiology, Hunan Cancer Hospital, School of Xiangya Medicine,
5 Central South University, Changsha 410013, Hunan, China.

6 ²Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha
7 410008, Hunan, China.

8 *Corresponding author. Email: 315977705@qq.com

9 † First author. Email: 527758565@qq.com

10 **Keywords:** tRNA-derived small RNAs (tsRNAs), small non-coding RNAs (sncRNAs),
11 nicotine exposure

12

13

14

15

16

17

18

19

20

21

22

23 **Abstract**

24 Nicotine use is highly prevalent and brings a huge burden on individuals, society, health-
25 care systems and economic development. The existing mechanisms underlying nicotine'
26 actions can't illuminate all basic and clinical problems thoroughly. Transfer RNA-derived
27 small RNAs (tsRNAs) is a novel class of small non-coding RNAs (sncRNAs), possessing
28 potential regulatory functions in various diseases. However, the roles of tsRNAs in nicotine
29 exposure have not been determined yet. In this study, firstly we established nicotine
30 exposure model by subcutaneously injecting (sc.) with 0.5mg/kg of nicotine twice daily for
31 14 consecutive days, and conducted some behavioral observations (the pain threshold and
32 body weight gains). Secondly, we identified the differentially expressed profiles of tsRNAs
33 in rat hippocampus on saline or nicotine delivery conditions by using ncRNA-Seq, and then
34 predicted the promising functions of the putative genes of the tsRNAs by bioinformatic
35 method. The results shown that there were 26 differentially expressed tsRNAs (7 up-
36 regulated and 19 down-regulated tsRNAs) (Fold change > 1.5; P < 0.05), of which the tRF-
37 5 was the most common type. Eight tsRNAs were selected to validate the sequencing
38 result by RT-qPCR. Then, based on the sequencing and RT-qPCR data, five candidate
39 tsRNAs (tRF-1-T28-His-GTG-1, tRF-5c-Glu-CTC-1, tRF-5c-Glu-CTC-3, tRF-5c-Gly-GCC-
40 2-M2, tRF-5c-Glu-TTC-4) were finally selected for further bioinformatic analysis. The GO
41 and KEGG pathway enrichment analysis suggested that the five candidate tsRNAs might
42 play regulatory roles through the cholinergic synapse pathways, dopaminergic synapse
43 pathways, etc. In conclusion, our results indicated that tsRNAs were dysregulated in the
44 rat hippocampus after nicotine exposure, and among them, tRF-5c-Glu-CTC-1 was the

45 most promising one, which might lay a novel foundation for further research into nicotine'

46 actions.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67 **Introduction**

68 According to the 2019 National Health Interview Survey (NHIS), an estimated 50.6
69 million U.S. adults aged ≥ 18 years (20.8%) reported currently using any tobacco product.
70 And Chinese CDC reported that in 2018, approximately 26.6% of people aged ≥ 15 years
71 were current smokers in China[1, 2]. Unfortunately, cigarette smoking remains the leading
72 cause of preventable disease and death in the United States[3]. From 1964–2012, an
73 estimated 17.6 million deaths were related to smoking, more than 480,000 deaths yearly[4].
74 Cigarette smoking is linked with diseases of nearly all organs of the body, such as various
75 cancers, respiratory diseases, cardiovascular diseases, neurological disorders, etc. In
76 addition to public health, smoking imposed a heavy burden on social economic. Experts
77 estimated that the annual societal costs attributable to smoking in the United States were
78 approximately \$300 billion, including \$168 billion for healthcare[5, 6].

79 Nicotine, the primary component of tobacco, exerts multiple biological functions through
80 which smoking increases risk for diseases. Nicotine exposure brings a series of changes
81 in body, including stimulating the adrenal glands, activating the reward circuits, modulating
82 neurotransmitters and receptors, and so on. The most well-known mechanisms of nicotine'
83 actions are the role of nicotinic cholinergic and dopaminergic system. In brief, nicotine can
84 bind and activate nicotinic acetylcholine receptors (nAChRs), which are widely distributed
85 throughout the nervous system and body, and thus result in the release of a variety of
86 neurotransmitters (dopamine, gamma-aminobutyric acid (GABA), serotonin, glutamate etc)
87 in the brain, particularly dopamine[7, 8]. Besides, nicotine exposure can also produce
88 additional neuroadaptations, including neuronal homeostatic mechanisms, neuronal

89 scaffolding proteins expression and epigenetic regulations[9-11]. However, there is still
90 much to be learned and done in order to fully understand how nicotine functions.

91 As the non-coding RNAs (ncRNAs) have been the hot topic in many areas in recent
92 years, many researchers pay their attention to the possibility of ncRNAs in nicotine use.
93 Chen et al reported that ncRNAs (miRNAs, lncRNAs and circRNAs) appear to form
94 complex interactions and impact the nicotine biosynthesis in tobacco[12], and Aliso
95 suggested that a pattern of miRNA/mRNA regulation occurs in the habenulo-
96 interpeduncular circuit during nicotine withdrawal[13]. As the major source of small
97 noncoding RNAs (sncRNAs), tRNA-derived small RNAs (tsRNAs) produced by cleavage
98 at different sites from mature or pre-tRNAs are gradually becoming the emerging research
99 direction[14, 15]. tsRNAs were first discovered in cancer patients until 1970s and at that
100 time, they were considered to be merely degradation products of tRNAs and have no
101 biological functions[16]. With the rapid development of high-throughput sequencing
102 technology, tsRNAs were revealed to function under various diseases, such as cancer,
103 neurodegenerative diseases, metabolic disorders, and others[15, 17, 18]. As to the specific
104 biological roles of tsRNAs, lots of researches have been done. For instance, Ivanov et al
105 suggested that tsRNAs could inhibit translation by displacing eIF4G/A from mRNA[19]; Kim
106 and his colleagues reported that LeuCAG3'tsRNA could modulate apoptosis by binding at
107 least two ribosomal protein mRNAs (RPS28 and RPS15)[20]. In general, several regulatory
108 mechanisms have been reported to date: 1) act like miRNAs to regulate gene expression,
109 2) regulate translation process, 3) function as epigenetic factors, 4) modulate apoptosis
110 and immune response, etc[14, 15, 21]. Although tsRNAs have been the hot area in recent

111 years, the majority of studies mainly focused on the roles of tsRNAs in cancer and
112 immune[17, 22, 23], and there have no relevant researches about the relationship between
113 tsRNAs and nicotine use or other addictive drugs thus far. Given its various roles under
114 physiopathological conditions, it's no doubt that exploring tsRNAs will provide a bran-new
115 insight into nicotine exposure research.

116 Therefore, the aim of our study is to identify the expression profile and potential roles of
117 tsRNAs in hippocampus after nicotine exposure. Using RNA-sequencing technologies, we
118 identified the expression profiles of tsRNAs, and then predicted the potential roles of the
119 candidate tsRNAs by bioinformatic methods. Our findings might reveal the potential
120 mechanisms and novel molecular targets underlying nicotine exposure, and provide a new
121 direction for future research in nicotine use.

122

123

124

125

126

127

128

129

130

131

132

133 **Materials and methods**

134 **Animals and experiment groups**

135 24 Adult male Sprague-Dawley rats (200±10g) were obtained from the Hunan SJA
136 Laboratory Animal Company (Hunan, China). And then the rats were housed in groups and
137 maintained for at least 5 days before the study in a temperature- (22±2°C) and humidity
138 controlled (50% relative humidity) environment with 12-h light/dark cycles. The rats had
139 food and water freely available. The experimental procedures were approved by the Animal
140 Care and Use Committee of Hunan Cancer Hospital and conducted in strict accordance
141 with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

142 To establish the nicotine exposure model, the rats in nicotine group (NI, n = 12) were
143 subcutaneously injected (sc.) with 0.5mg/kg (0.5 mg/ml) of nicotine twice daily at 08: 00-
144 09:00 am and 16:00-17:00 pm for 14 consecutive days. The rats in normal saline group
145 (NS, n = 12) were injected with the same volume of 0.9% saline at the same time points.

146 To analyze the effects of nicotine on sensation, hind paw mechanical withdrawal
147 thresholds were measured every other day using von Frey filaments test (Italy, UGO Basile)
148 and the test was always performed between 13:00-16:00 pm[24]. The results were
149 converted to the 50% of paw withdrawal threshold (50%PWT). The body weight was tested
150 every day before the morning injection.

151 **Tissue Collection and RNA isolation**

152 On day 14, 1h after the morning injection, the rats in both groups were decapitated under
153 deep anesthesia by 4% isoflurane inhalation for 3 minutes. The hippocampus (n=6, each
154 group) were quickly dissected and collected on ice and fresh frozen in liquid nitrogen. Total

155 RNA was extracted from frozen tissues using Trizol (Invitrogen, CA, USA) according to the
156 manufacturer's instructions. The quantity and concentration of each RNA sample were
157 assessed using a NanoDrop ND-1000 Spectrophotometer (Thermo, USA) and the integrity
158 was checked by agarose gel electrophoresis.

159 **Library preparation and sequencing**

160 The following treatments were performed before library preparation for total RNA
161 samples to remove RNA modifications that interfered with small RNA-seq library
162 construction: 3'-aminoacyl (charged) deacylation to 3'-OH for 3' adaptor ligation, 3'-cP (2,3
163 -cyclic phosphate) removal to 3'-OH for 3' adaptor ligation, 5'-OH (hydroxyl group)
164 phosphorylation to 5'-P for 5'-adaptor ligation, m1A and m3C demethylation for efficient
165 reverse transcription. Sequencing libraries were size-selected for the RNA biotypes to be
166 sequenced using an automated gel cutter, which were qualified and absolutely quantified
167 using an Agilent Bio-Analyzer 2100 (Invitrogen, CA, USA). To generate the mature tRNA
168 libraries, we removed the predicted intronic sequences (if present) and added an additional
169 3-terminal "CCA" to each tRNA. To generate the precursor tRNA libraries, we included 40
170 nucleotides of flanking genomic sequence on either side of the original tRNA sequence.

171 **Sequencing data analysis**

172 Image analysis and base calling were performed using Solexa pipeline v1.8 software
173 (Off-Line Base Caller software, v1.8). Sequencing quality was examined by FastQC
174 software and trimmed reads (pass Illumina quality filter, trimmed 3-adaptor bases by
175 cutadapt) were aligned to mature-tRNA and pre-tRNA sequence getting from the Genomic
176 tRNA Database using Novo Align software (v2.07.11). The remaining reads were aligned

177 to transcriptome sequences (mRNA/rRNA/snRNA/snoRNA/piRNA/miRNA). The
178 abundance of tsRNAs were evaluated using their sequencing counts and normalized as
179 counts per million of total aligned reads (CPM). The tsRNAs differentially expressed are
180 screened based on the count value with R package edgeR. Pie plots, Venn plots,
181 Hierarchical clustering, Scatter plots and Volcano plots are performed in R or perl
182 environment for statistical computing and graphics of the expressed tsRNAs. The ncRNA-
183 seq was performed by Kangcheng Bio-tech (Shanghai, China).

184 **RT-qPCR validation**

185 RT-qPCR was conducted to confirm the sequencing data. Eight differentially expressed
186 tsRNAs were chosen for RT-qPCR. U6 small nuclear RNA (snRNA) was used as a
187 reference. The RNA was reversely transcribed to cDNA using an rtStar™ tRF&tiRNA
188 Pretreatment Kit (Arraystar, MD, USA) and an rtStar First-Strand cDNA Synthesis Kit (3'
189 and 5' adaptor) (Arraystar, MD, USA) according to the manufacturer's instructions. Then,
190 RT-qPCR was performed using 2XPCR master mix (Arraystar, MD, USA) with a ViiA7 Real-
191 time PCR System (Applied Biosystems, CA, USA). The parameter settings were as follows:
192 95°C denaturation (10 min), 40 amplification cycles at 95°C (10 s), and 60°C (60 s). After
193 the amplification reaction was finished, the procedure was performed as follows: 95°C (10
194 s), 60°C (60 s), and 95°C (15 s). All reactions were performed in triplicate. And the
195 sequences of all primers are presented in supplementary table S1.

196 **Bioinformatic Prediction**

197 The five significantly differentially expressed tsRNAs (Fold change > 1.5 and *P*-value <
198 0.05) selected according to the results of the sequencing and RT-qPCR were analyzed

199 using bioinformatic methods. According to a previous study[25], two common algorithms
200 were used to predict the tsRNA targets, including TargetScan and miRanda. A graph of the
201 tsRNA/mRNA network was derived using the Cytoscape software (version 3.5.1, the
202 Cytoscape Consortium, San Diego, CA, USA) to visualize these relationships. Then, to
203 forecast the biological annotation and pathway of the putative targets, we used Gene
204 Ontology (GO) to reveal the biological process, cellular component, and molecular function
205 of the target mRNAs. Significant pathways were identified using the pathways in the Kyoto
206 Encyclopedia of Genes and Genomes database (KEGG).

207 **Statistical analysis**

208 Statistical analysis was performed using Graphpad prism software (version 3.0, Chicago,
209 IL, USA). The behaviors and PCR results are shown as the mean \pm standard error of the
210 mean (SEM). Two-tailed Student's t-test was used to compare the significant differences
211 between the two groups. The level of significance was set at $P < 0.05$.

212 **Database and Accession Numbers**

213 The raw data of the tsRNA-Seq in our study were deposited at the NCBI Gene
214 Expression Omnibus (GEO) under the accession number GSE162402.

215

216

217

218

219

220

221 **Results**

222 **Behavioral observations: the effects of nicotine on sensation and body weight**

223 The mechanical test revealed that on day 5, the 50%PWT of the nicotine group was
224 significantly higher than that of the saline group (n = 12 in each group, *** $P < 0.001$), and
225 this state continued to day 13 (Fig. 1a). The result indicated that nicotine exposure could
226 change the pain sensation and produce an analgesic effect. Weight measure shown that
227 on day 4, the weight increase of the nicotine group was lower, compared with the saline
228 group (n = 12 each group, ** $P < 0.01$), suggesting that nicotine exposure might impact the
229 energy metabolism and appetite. In the days that followed, there was no significant
230 difference about weight increase between both groups (Fig. 1b).

231

232 **Expression profiles of tsRNAs in hippocampus of nicotine and saline rats**

233 The scatter plots were created presenting the tsRNA expression variation between the
234 nicotine group and saline group using the fold change (n=3 in each group, shown in Fig.
235 2a). According to the criteria of a \log_2 (fold change) > 1.5 and a P -value < 0.05 , a total of
236 26 differentially expressed tsRNAs were finally identified, including 7 up-regulated and 19
237 down-regulated tsRNAs (Fig. 2b). And the hierarchical clustering heat-map for the 26
238 differentially expressed tsRNAs was displayed in Figure 2c. The detailed information on
239 the top 5 up-regulated and 10 down-regulated tsRNAs ranked by fold change were
240 presented in Table 1. In Figure 2d, the Venn diagram presented that a total of 354 were
241 commonly expressed tsRNAs in both groups, 73 tsRNAs specifically expressed in nicotine
242 group, and 24 tsRNAs specifically expressed in saline group.

243

244 **Catalog of tRFs/tiRNAs in both groups**

245 The pie chart demonstrates the percentage of each subtype of the tsRNAs expressed
246 uniquely in two groups (Fig. 3a-b). Overall, except for tRF-2, the expression levels of other
247 tsRNAs (tRF-1, tRF-3, tRF-5, tiRNA-3, tiRNA-5) in Group nicotine were increased, as
248 compared to Group saline. In both groups, tRF-5 were the most common type. The read
249 counts and read length for each unique read in both groups are shown in the bar chart of
250 sequence read length distribution (Fig. 3c-d). We found that the length distribution of
251 tsRNAs in both groups mainly concentrate on 20-24nt. The number of tsRNA subtypes
252 against tRNA iso-decoders and the frequency of subtypes against the length of the tsRNA
253 were shown by the stacked bar charts (Fig. 3e-h). And in these charts, we discovered that
254 Glu-CTC, Glu-TTC, Gly-CCC, Gly-GCC, His-GTG are the most common tRNA iso-
255 decoders of tsRNAs in both groups.

256

257 **Validation for the differentially expressed tsRNAs (DEtsRNAs)**

258 To validate the sequencing data, RT-qPCR was performed. Eight tsRNAs (3 upregulated
259 and 5 downregulated) were chosen according to their raw expression level, the fold change
260 value and the *p*-value (shown in Table 2). As a result, tRF-1-T28-His-GTG-1 was
261 significantly up-regulated, and tRF-5c-Glu-CTC-1, tRF-5c-Glu-CTC-3, tRF-5c-Gly-GCC-2-
262 M2, tRF-5c-Glu-TTC-4 were down-regulated in Group nicotine, compared with Group
263 saline (n=3 in each group, *p* < 0.05) (Fig. 4a-b). The comparison of the results of
264 sequencing and PCR were displayed in Table 3, and the overall results were in line with

265 the sequencing data.

266

267 **Bioinformatic Prediction**

268 The five significantly DEtsRNAs, namely, tRF-1-T28-His-GTG-1, tRF-5c-Glu-CTC-1,
269 tRF-5c-Glu-CTC-3, tRF-5c-Gly-GCC-2-M2, tRF-5c-Glu-TTC-4 were selected for further
270 bioinformatic analysis. First, we predicted the potential target genes of these five tsRNAs
271 based on TargetScan and Miranda algorithms, and the putative genes with context less
272 than -0.4 were displayed (Fig. 5). We found that there existed interactions among these
273 five candidate tsRNAs, and particularly tRF-5c-Glu-CTC-1 and tRF-5c-Glu-CTC-3 shared
274 plentiful common genes. Secondly, we conducted the GO and pathway enrichment
275 analysis of all the target genes of these five candidate tsRNAs. In terms of molecular
276 function, the general results indicated that the most significant enrichment and the most
277 meaningful terms were protein binding (GO:0005515) (see Fig. 6a, c, e, g, j). As to the
278 cellular component of these candidate tsRNAs, the results shown that the up-regulated
279 tRF-1-T28-His-GTG-1 was mainly found in spindle (GO:0005819) and intracellular
280 (GO:0005622) (Fig. 6a), whereas, the four down-regulated tsRNAs (tRF-5c-Glu-CTC-1,
281 tRF-5c-Glu-CTC-3, tRF-5c-Gly-GCC-2-M2, tRF-5c-Glu-TTC-4) were usually found in
282 intracellular (GO:0005622) and intracellular part (GO:0044424) (Fig. 6c, e, g, j). Then the
283 major biological processes of these candidate tsRNAs were involved in localization
284 (GO:0051179), establishment localization (GO:0051234), transport (GO:0006810) and cell
285 surface receptor signaling pathway (GO:0007166) (Fig. 6a, c, e, g, j).

286 According to the KEGG enrichment analysis, the most significantly enriched pathways

287 of tRF-1-T28-His-GTG-1 were protein processing in endoplasmic reticulum, cell adhesion
288 molecules, and cocaine addiction (Fig. 6b). For the four down-regulated tsRNAs (tRF-5c-
289 Glu-CTC-1, tRF-5c-Glu-CTC-3, tRF-5c-Gly-GCC-2-M2, tRF-5c-Glu-TTC-4), MAPK
290 signaling pathway, Axon guiding, dopaminergic synapse, cholinergic synapse,
291 glutamatergic synapse, neurotrophin signaling pathway are mainly identified in general (Fig.
292 6d, f, h, k). Two important pathways (the cholinergic synapse and dopaminergic synapse
293 pathways) of tRF-5c-Glu-CTC-1 involved in the mechanism of nicotine' actions were
294 displayed in Figure 7, and the other major pathways were shown in supplementary Figure
295 S1.

296

297

298

299

300

301

302

303

304

305

306

307

308

309 **Discussion**

310 In this study, we reported the expression profiles of tsRNAs in the rat hippocampus after
311 nicotine exposure for the first time. The sequencing data revealed that there were 26
312 differentially expressed tsRNAs, involving 7 up-regulated and 19 down-regulated tsRNAs,
313 in the rat hippocampus after nicotine exposure. Subsequently, 8 DEtsRNAs were chosen
314 to validate by RT-qPCR and among them, 5 candidate DEtsRNAs for further bioinformatic
315 predictions. The GO and KEGG pathway analysis demonstrated that the potential targeted
316 genes and the putative pathways of the 5 DEtsRNAs mainly focused on several critical
317 signaling channels, which played important roles in nicotine' actions. Taken together, our
318 findings suggest that these dysregulated tsRNAs may play regulatory roles on how nicotine
319 functions.

320 There is a consensus that nicotine exposure can induce changes in pain perception and
321 body weight in animal models and human studies[26-28]. Recent research indicated that
322 nAChRs agonists (such as nicotine, epibatidine, choline) might make up a novel class of
323 analgesics for pain management[29-31]. In our previous research, we found that short-
324 term use of nicotine could produce analgesic effects, but long-term use or withdrawal led
325 to hypersensitivity, and further investigation indicated that nicotine could alter pain
326 sensitivity by affecting the expression of the pain related factor[24]. In this study, when the
327 rats were continuously injected with nicotine, the paw withdrawal threshold increased and
328 the body weight gains decreased, which was in accordance with our previous study.

329 Nicotine exerts its functions largely through the widespread nAChRs. Substantial
330 researches suggested that nicotine exposure could upregulate nAChRs by multiple

331 processes, including changes in receptor assembly, trafficking, and degradation[32-34]. In
332 recent years, genetic factors is becoming the research focus about nAChRs, and variants
333 in the CHRNA5-CHRNA3-CHRNA4 gene cluster are the most studied associated with
334 nicotine' actions[35, 36]. Besides, Cameli et al pointed out that genetic variations in
335 CHRNA7 and CHRFAM7A were related to nicotine addiction[10].In our study, we found
336 that tRF-5c-Glu-CTC-1, tRF-5c-Glu-CTC-3, tRF-5c-Glu-TTC-4 might be involved in the
337 cholinergic synapse pathway, and in turn influence the excitability of neurons and glial cells.
338 Further analysis indicated that the putative genes of these above tsRNAs included CHRM1,
339 CHRM3, CHRNA3, CHRNA4 and CHRNA7, which encoded variant subunits of nAChRs.
340 So we presumed that tRF-5c-Glu-CTC-1, tRF-5c-Glu-CTC-3, tRF-5c-Glu-TTC-4 might
341 function in nicotine' actions by modifying the genes expression of nAChRs' subunits, thus
342 influencing the structure and activity of nAChRs.

343 In addition to nAChRs, there existed some other possible mechanisms involved in nicotine'
344 actions. On the one hand, nicotine exposure can produce widespread neuroadaptations in
345 nervous system, including dopaminergic (DA) synapses, GABAergic circuitry,
346 glutamatergic synapses, and so on. On the other hand, these neuroadaptations were in
347 turn to participate in the nicotine' actions[37-39]. Recent studies shown that genetic
348 variations in DA, GABA could regulate nicotine' actions. For instance, Bühler and his
349 colleagues summarized that apart from nAChRs genes, variations in ANKK1, DRD2 and
350 GABA were likewise associated with nicotine-related phenotypes[35]. Liu et al constructed
351 the networks of candidate genes associated with nicotine addiction, and concluded that
352 cholinergic receptors (CHRNA1, CHRNA4, CHRNA7), dopamine receptors (DRD1, DRD2,

353 DRD3) and GABA receptors (GABRA1, GABRA2, GABRA4) were involved in diverse
354 biological functions[40]. Other researches about genetic modulations in DA (COMT, GCH1,
355 and DRD2) and GABA indicated these changes could affect the modulation of DA in pain
356 pathway[41, 42]. In our study, we predicted the target genes of these five candidate tsRNAs,
357 and found that tRF-5c-Glu-CTC-1 might regulate the expressions of COMT, DRD2,
358 GABRA4, whereas tRF-5c-Glu-CTC-3 might regulate DA related genes COMT and DRD2.
359 The KEGG pathway analysis indicated that tRF-5c-Glu-CTC-1 probably participated in the
360 dopaminergic synapse, GABAergic synapses and glutamatergic synapses pathways, while
361 tRF-5c-Glu-CTC-3 might merely modulate the dopaminergic synapse and glutamatergic
362 synapses pathways, not GABAergic synapses.

363 Apart from the above neurotransmitters, previous researches suggested that nicotine
364 shared the similar functional molecules, signal paths and acting sites with some other
365 addictive drug, such as cocaine, morphine[11, 43, 44]. We found in our study that the
366 candidate tsRNAs could modulate the pathways of cocaine, morphine and amphetamine
367 addiction. To be specific, tRF-5c-Glu-CTC-1 took part in all the three paths of cocaine,
368 morphine and amphetamine addiction, tRF-1-T28-His-GTG-1 and tRF-5c-Glu-CTC-3 took
369 part in cocaine addiction, and tRF-5c-Gly-GCC-2-M2 in morphine addiction. Hence, we
370 speculated that those candidate tsRNAs might likely contribute to nicotine addiction in a
371 similar way. More researches are needed.

372 According to the KEGG pathway analysis, we also discovered that except the above
373 pathways, the putative genes of the five candidate tsRNAs were also enriched in some
374 other critical paths, such as MAPK signaling pathway, mTOR signaling pathway,

375 neurotrophin signaling pathway, which have been suggested to involve nicotine' actions in
376 body[45-47]. And further analysis indicated that the majority of the putative pathways of
377 tRF-5c-Glu-CTC-1 were associated with the previously known mechanisms of nicotine'
378 actions, so we regard tRF-5c-Glu-CTC-1 as the most promising candidate for further study
379 in nicotine' actions.

380 Generally, tsRNAs with lengths of 18–40 nucleotides, include two main types based on
381 the length and cleavage sites on tRNA or pre-tRNA: tRNA-derived fragments (tRFs) and
382 tRNA-derived, stress-induced RNAs (tiRNAs). tiRNAs are usually the products of
383 angiogenin cleavage of mature tRNAs at the anticodon site during stress, which contain
384 two subtypes tiRNA-5 and tiRNA-3. While tRFs derive from cleavage on any sites of mature
385 or pre-tRNAs, which contain four subtypes tRF-5, tRF-3, tRF-1, tRF-2[14, 15, 48]. Growing
386 evidence indicated that the functions of tsRNAs depended on their subtype and specific
387 subcellular localization. Some researchers stated that cytosolic and mitochondrial tiRNAs
388 could repress protein translations and be associated with apoptosis initiation[49, 50].
389 Kumar et al remarked that in HeLa cell line, tRF-5s are mostly nuclear while tRF-3s and -
390 1s are cytoplasmic, and further study in human HEK 293 cells suggested that tRF-5s and
391 tRF-3s are associated with Argonautes 1, 3 and 4, and then target mRNAs in a manner
392 similar to miRNAs[51]. Zhang and his colleagues reported that in monocytes/dendritic Cells,
393 td-piR^(Glu) (tRF-5) could interact with PIWI protein and play a role in regulation of chromatin
394 remodeling in somatic cells, just like piRNAs[52]. According to the known literature of
395 tsRNAs as well as our data, the most promising candidate tRF-5c-Glu-CTC-1 belonged to
396 tRF-5, so we postulated that it's likely that tRF-5c-Glu-CTC-1 might function by interacting

397 with Ago proteins or PIWI protein, and have post-transcriptional regulations similarly to
398 miRNAs or epigenetic modulations like piRNAs. In nicotine exposure model, nicotine
399 exposure could upregulate the expression of nAChRs and downregulate tRF-5c-Glu-CTC-
400 1 whose downstream genes CHRM1, CHRM3, CHRNA4 and CHRNA7 could encode the
401 subunits of nAChRs shown in our data. Given the negative regulatory relationship between
402 tRF-5c-Glu-CTC-1 and its putative genes, we conjecture that nicotine exposure may
403 reduce the biosynthesis of tRF-5c-Glu-CTC-1, then alleviate its suppression on the genes
404 expression of nAChRs subunits, and thereby upregulate nAChRs, which lay the foundation
405 for nicotine' actions. Further research is needed in future.

406 There are some limitations about our study. First, we only detect the profiles of tsRNAs
407 on nicotine exposure condition, not nicotine withdrawal, and lack the dynamic detection of
408 tsRNAs at different time point. Secondly, our research is preliminary and further functional
409 research is needed to identify the specific locations and functions of the candidate tsRNAs
410 in vitro and in vivo. Finally, detection of tsRNAs in human trial is hopefully to conduct in
411 future.

412 To sum up, our study provided the differentially expressed profiles of tsRNAs in rat
413 hippocampus after nicotine exposure for the first time. Further bioinformation analysis
414 revealed that the tsRNAs might be a new class of regulatory molecules in nicotine related
415 researches, which might function by regulating some important signaling pathways, such
416 as the cholinergic synapse, dopaminergic synapse. Among them, tRF-5c-Glu-CTC-1 is the
417 most promising one, and probably act in a manner of miRNAs or piRNAs. In a word, our
418 study paves a new road for research into nicotine' actions, especially in addiction and

419 nicotine-mediated analgesia, and provides novel modulatory targets for this area.

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441 **Supplementary information**

442 Additional file 1: Table S1. Sequences of primers used for RT-qPCR assay

443 Additional file 2: Figure S1. Mapping of several important putative pathways of the 5
444 candidate tsRNAs

445 **Abbreviations:**

446 tsRNAs: tRNA-derived small RNAs; sncRNAs: small noncoding RNAs; DEtsRNAs:
447 differentially expressed tsRNAs; tRFs: tRNA-derived fragments; tiRNAs: tRNA-derived,
448 stress-induced RNAs; PWT: paw withdrawal threshold; CPM: counts per million of total
449 aligned reads; BP: Biological process; CC: Cellular component; MF: Molecular function;
450 GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; RT-qPCR:
451 Quantitative real-time PCR.

452 **Acknowledgements**

453 Not applicable.

454 **Authors' contributions**

455 J-LS performed the experiments, collected and analyzed the data, and drafted the
456 manuscript. Y-XF performed the experiments. CS and W-YZ revised the manuscript. J-FY
457 designed the study, supervised the project and experiments and revised the manuscript.
458 All authors read and approved the final manuscript.

459 **Funding**

460 This work was supported by grants from Hunan Province:"100 Talents Plan" on
461 Overseas High-Level Talents Introduction (20174300015).

462 **Availability of data and materials**

463 Please contact the author for data requests

464 **Ethics approval and consent to participate**

465 All experiments were approved by the Animal Care and Use Committee of Hunan Cancer
466 Hospital, and performed following the guidelines of the National Institutes of Health Guide
467 for the Care and Use of Laboratory Animals.

468 **Consent for publication**

469 Not applicable.

470 **Competing interests**

471 The authors declare that they have no competing interests.

472

473

474

475

476

477

478

479

480

481

482

483

484

485 **References**

- 486 1. Monica E. Cornelius, Teresa W. Wang, Ahmed Jamal, Caitlin G. Loretan, Linda J.
487 Neff. Tobacco Product Use Among Adults — United States, 2019. Morbidity and
488 Mortality Weekly Report, 2020. 69(46):1736-42.
- 489 2. Chinese CDC. 2018 China Tobacco Control Report. http://www.chinacdc.cn/jkzt/sthd_3844/slhd_4156/201905/t20190530_202932.html. Accessed 30 May 2019.
- 491 3. US Department of Health and Human Services. The health consequences of
492 smoking-50years of progress: a report of the Surgeon General. Atlanta, GA:2014.
493 https://www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK179276.pdf
- 494 4. Theodore R.H, Rafael M, Kenneth E. W, Clare M, Jihyoun J, Suresh H.M, and David
495 T.L. Tobacco control and the reduction in smoking-related premature deaths in the
496 United States, 1964-2012. JAMA, 2014. 311(2):164-71.
- 497 5. National Institute on Drug Abuse. Tobacco, Nicotine, and E-Cigarettes Research
498 Report. 2020:1-59.
- 499 6. Xin X, Ellen E.B, Sara M.K, Sean A.S and Terry F.P. Annual healthcare spending
500 attributable to cigarette smoking: an update. Am J Prev Med, 2015. 48(3):326-33.
- 501 7. Ruthie E.W, Shannon L.W, Mariella D.B, John A.D. Nicotinic acetylcholine receptors
502 and nicotine addiction: A brief introduction. Neuropharmacology, 2020:1-30.
- 503 8. Roger L. Papke. Merging old and new perspectives on nicotinic acetylcholine
504 receptors. Biochemical Pharmacology, 2014. 89(1):1-11.
- 505 9. Tamaki Hayase. Epigenetic mechanisms associated with addiction-related
506 behavioural effects of nicotine and/or cocaine: implication of the endocannabinoid

- 507 system. *Behav Pharmacol*, 2017. 28(7):493-511.
- 508 10. Cameli C, Elena B, Maria D.P, Giuliano G, Stefano C, et al. Genetic variation in
509 CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to
510 varenicline treatment. *Eur J Hum Genet*, 2018. 26(12):1824-31.
- 511 11. Ju W, Wenji Y, Ming D.L. Genes and pathways co-associated with the exposure to
512 multiple drugs of abuse, including alcohol, amphetamine/methamphetamine,
513 cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses. *Mol*
514 *Neurobiol*, 2011. 44(3):269-86.
- 515 12. Xi C, Shuo S, Fangjie L, Enhui S, Lu L, et al. A transcriptomic profile of topping
516 responsive non-coding RNAs in tobacco roots (*Nicotiana tabacum*). *BMC Genomics*,
517 2019. 20(856):1-14.
- 518 13. Alison P.C, Junko T, Rubing Z.S, Ciearra B.S, Susanna M, et al. Integrated miRNA-
519 /mRNA-Seq of the Habenulo-Interpeduncular Circuit During Acute Nicotine
520 Withdrawal. *Sci Rep*, 2020. 10(813):1-14.
- 521 14. Hak K.K, Ji-Hyun Y and Mark A.K. Transfer RNA-Derived Small RNAs: Another
522 Layer of Gene Regulation and Novel Targets for Disease Therapeutics. *Mol Ther*,
523 2020. 28(11):1-18.
- 524 15. Siqi L, Zhengping X and Jinghao S. tRNA-Derived Small RNA: A Novel Regulatory
525 Small Non-Coding RNA. *Genes* 2018. 9(246):1-15.
- 526 16. Ernest B, B.S Baliga, Charles W.G, C.W Kuo, Sidney B, et al. High Turnover Rate
527 of Transfer RNA in Tumor Tissue. *CANCER RESEARCH*, 1977. 37:3362-66.
- 528 17. Yangyang C, Yue H, Xiaowei W, Mingjie Z, Yiqin X, et al. Hypoxia-induced tRNA-

- 529 derived fragments, novel regulatory factor for doxorubicin resistance in triple-
530 negative breast cancer. *J Cell Physiol*, 2018:1-12.
- 531 18. Kanako S, Sherif R, Kuniyasu N and Teiji T. Stress Induced tRNA Halves (tiRNAs)
532 as Biomarkers for Stroke and Stroke Therapy; Pre-clinical Study.
533 *Neuroscience*,2020.434: 44-54.
- 534 19. Pavel I, Mohamed M.E, Judit V, Steven P.G and Paul A. Angiogenin-induced tRNA
535 fragments inhibit translation initiation. *Mol Cell*, 2011. 43(4):613-23.
- 536 20. Hak K.K, Gabriele F, Shengchun W, Wei W, Yue Z, et al. A transfer-RNA-derived
537 small RNA regulates ribosome biogenesis. *Nature*, 2017. 552(7683):57-62.
- 538 21. Shawn M.L, Marta M.F and Pavel I. The role of RNA modifications in the regulation
539 of tRNA cleavage. *FEBS Lett*, 2018. 592(17):2828-44.
- 540 22. Domenico R, Judith L and Sandra B. Emerging roles of novel small non-coding
541 regulatory RNAs in immunity and cancer. *RNA Biol*, 2020. 17(8):1196-1213.
- 542 23. Paraskevi K, Panagiotis G.A, Sotirios G.P, Vasiliki P, Andreas S, Christos K.K. A
543 novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility
544 as a molecular prognostic biomarker in chronic lymphocytic leukemia. *Clin*
545 *Biochem*,2020. 85:20-26.
- 546 24. Yanping Z, Jinfeng Y, Alec S, Robert W, Jiao W, et al. The mechanism of chronic
547 nicotine exposure and nicotine withdrawal on pain perception in an animal model.
548 *Neurosci Lett*, 2020. 715:1-22.
- 549 25. Licong S, Xi Xia H, Wenjun Z and Yi Z. Expression profiles of tRNA-derived
550 fragments and their potential roles in ovarian endometriosis. *Epigenomics*, 2020.

- 551 123(3):1-15.
- 552 26. Joseph W.D, Bryan W.H, Emily L.Z, Jesse D.K, and Stephen A.M. Acute analgesic
553 effects of nicotine and tobacco in humans: a meta-analysis. *Pain*, 2016.
554 157(7):1373-81.
- 555 27. Iboro C.U, Claire A.D, Brooke A.M, Chandrika A, Keith G, et al. Nicotinic modulation
556 of descending pain control circuitry. *Pain*, 2017. 158(10):1938-50.
- 557 28. Petros Y.D, Maria P, Constantinos A, Christina T, Georgia K, et al. Effects of cigarette
558 smoke exposure and its cessation on body weight, food intake and circulating leptin,
559 and ghrelin levels in the rat. *Nicotine Tob Res*, 2013. 15(1):206-12.
- 560 29. Matthews AM, Fu R, Dana T, Chou R. Intranasal or transdermal nicotine for the
561 treatment of postoperative pain. *Cochrane Database Syst Rev*, 2016(1):1-125.
- 562 30. Weiwei L, Jingyi C, Benjamin H.W, Lanting H, Jing F and Yun W. Antinociceptive
563 effects of novel epibatidine analogs through activation of alpha4beta2 nicotinic
564 receptors. *Sci China Life Sci*, 2018. 61(6):688-695.
- 565 31. Deniz B, Mine S.G, Pamela F, Roger L.P and M. Imad D. New Insights on Neuronal
566 Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on
567 alpha7 nAChRs. *Curr Neuropharmacol*, 2018. 16(4):415-425.
- 568 32. Brandon H, Rahun S, Weston A.N, Crystal N.D, Diana F.G. Nicotine exploits a COPI-
569 mediated process for chaperone-mediated up-regulation of its receptors. *J Gen
570 Physiol*, 2014. 143(1):51-66.
- 571 33. Brandon J. Henderson, Henry A. Lester. Inside-out neuropharmacology of nicotinic
572 drugs. *Neuropharmacology*, 2015. 96:178-193.

- 573 34. Morgane B, Sylvie G, Monica Mameli E, Isabelle C.T, Nicolas M, et al. Long-term
574 effects of chronic nicotine exposure on brain nicotinic receptors. Proceedings of the
575 National Academy of Sciences, 2007. 104(19):8155-60.
- 576 35. Kora M.B, Elena G, Fernando R.F, Victor E.A, Javier C.C and Jose Antonio L.M.
577 Common single nucleotide variants underlying drug addiction: more than a decade
578 of research. Addict Biol, 2015. 20(5):845-71.
- 579 36. Bader C, Kees J.K, Scott M, Philip A.S, Alexandra P, et al. Low smoking-exposure,
580 the adolescent brain, and the modulating role of CHRNA5 polymorphisms. Biol
581 Psychiatry Cogn Neurosci Neuroimaging, 2019. 4(7):672-9.
- 582 37. Jieun K, Ju H.Y, In Soo R, Sumin S, Sunghyun K and Eun S.C. Interactions of
583 Glutamatergic Neurotransmission and Brain-Derived Neurotrophic Factor in the
584 Regulation of Behaviors after Nicotine Administration. Int J Mol Sci, 2019. 20(12):1-
585 12.
- 586 38. Beverley M.H, Brian A.W, Rahul S, Bruce N.C, Cheng X, et al. Transcriptional
587 regulation by nicotine in dopaminergic neurons. Biochem Pharmacol, 2013.
588 86(8):1074-83.
- 589 39. Yijin Y, Nicole A.B, Veronica J.K and Ryan M.D. Differential Nicotinic Modulation of
590 Glutamatergic and GABAergic VTA Microcircuits. eneuro, 2019. 6(6):1-12.
- 591 40. Meng L, Rui F, Xinhua L, Feng C, Ju W. Pathways and networks-based analysis of
592 candidate genes associated with nicotine addiction. PLoS One, 2015. 10(5):1-17.
- 593 41. Roel R.I. van Reij, Elbert A.J. Joosten and Nynke J. van den Hoogen. Dopaminergic
594 neurotransmission and genetic variation in chronification of post-surgical pain. Br J

- 595 Anaesth, 2019. 123(6):853-864.
- 596 42. Caijuan L, Yanying L, Yi T, Shiqin X, Xiaofeng S, et al. The Etiological Contribution
597 of GABAergic Plasticity to the Pathogenesis of Neuropathic Pain. *Molecular Pain*,
598 2019:1-28.
- 599 43. Dragana J, Valentina B, Anna R.C, Ezio C. Nicotine, cocaine, amphetamine,
600 morphine, and ethanol increase norepinephrine output in the bed nucleus of stria
601 terminalis of freely moving rats. *Addict Biol*, 2019. 26(1):1-9.
- 602 44. Christian P.M and Judith H. The role of serotonin in drug use and addiction. *Behav*
603 *Brain Res*, 2015. 277:146-92.
- 604 45. Jenni H, Teemu P, Ida S, Richa G, Jadwiga B, et al. Genome-wide association study
605 in Finnish twins highlights the connection between nicotine addiction and
606 neurotrophin signaling pathway. *Addict Biol*, 2019. 24(3):549-561.
- 607 46. Yonghong D, Wenhui S, Guannan X, Ailan Y, Qinghe W and Zongwang Z. CX3CR1
608 Mediates Nicotine Withdrawal-Induced Hyperalgesia via Microglial P38 MAPK
609 Signaling. *Neurochem Res*, 2015. 40(11):2252-61.
- 610 47. Xi X, Xueliang S, Baohui Z, Hui Z, Tao Z. Nicotine alleviates chronic stress-induced
611 anxiety and depressive-like behavior and hippocampal neuropathology via
612 regulating autophagy signaling. *Neurochem Int*, 2018. 114:58-70.
- 613 48. Yijing S, Xiuchong Y, Linwen Z, Tianwen L, Zhilong Y and Junming G. Transfer RNA-
614 derived fragments and tRNA halves: biogenesis, biological functions and their roles
615 in diseases. *J Mol Med (Berl)*, 2018. 96(11):1167-76.
- 616 49. Sherif R, Teiji T and Kuniyasu N. The cell and stress-specific canonical and

617 noncanonical tRNA cleavage. *J Cell Physiol*, 2020:1-15.

618 50. Sherif R., Kuniyasu N and Teiji T. tRNA cleavage: a new insight. *Neural Regen Res*,
619 2020. 15(1):47-52.

620 51. Pankaj K, Jordan A, Suresh B.M and Anindya D. Meta-analysis of tRNA derived
621 RNA fragments reveals that they are evolutionarily conserved and associate with
622 AGO proteins to recognize specific RNA targets. *BMC Biology*, 2014. 12(78):1-14.

623 52. Xue Z, Xin H, Chao L, Jun L, Qifei H, et al. IL-4 Inhibits the Biogenesis of an
624 Epigenetically Suppressive PIWI-Interacting RNA To Upregulate CD1a Molecules
625 on Monocytes/ Dendritic Cells. *J Immunol*, 2016. 196(4):1591-603.

626

627

628

629

630

631

632

633

634

635

636

637

638

639 **Figure legends**

640 **Figure 1.** Behavioral observations. a) 50% paw withdrawal threshold (PWT) of both groups.

641 The mechanical pain sensation of each rat was measured and recorded by 50%PWT, and

642 the data were presented as mean \pm SEM (n = 12 in each group), *** $P\leq 0.001$. b) Body weight

643 changes of both groups. The body weight of each rat was recorded every day, and the

644 difference values within every 4 days were calculated and analyzed using Student's t-test.

645 The data were presented as mean \pm SEM (n = 12 in each group), ** $P\leq 0.01$.

646

647 **Figure 2.** Expression profiles of tsRNAs sequencing data in both groups (n=3). a) The

648 scatter plots of differentially expressed tsRNAs. tsRNAs above the top line (red dots, up-

649 regulation) or below the bottom line (green dots, down-regulation) indicate more than 1.5-

650 fold change between the two compared groups. Gray dots indicate non-differentially

651 expressed tsRNAs. b) The volcano plots of differentially expressed tsRNAs. The vertical

652 dotted lines manifest 1.5-fold changes (log₂ scaled) up and down, respectively, and the

653 horizontal dotted line shows a p-value of 0.05 (-log₁₀ scaled). The red and green points

654 denote the significantly up- and down-regulated tsRNAs. c) Hierarchical clustering heat-

655 map for the 26 differentially expressed tsRNAs. The up- and down-regulated tsRNAs are

656 colored in red and blue, respectively. d) Venn diagram based on the number of commonly

657 expressed and specifically expressed tsRNAs. The number of tsRNAs commonly

658 expressed in both groups were shown in red color, the specifically expressed tsRNAs in

659 nicotine group in blue color, and the specifically expressed tsRNAs in saline group in

660 orange color.

661

662 **Figure 3.** Differences and characterizations of tsRNAs expression profiles between both
663 groups. a) and b) The Pie charts of tsRNAs subtypes in saline and nicotine group. The
664 colors represent the tsRNAs subtypes. The values in brackets represent the numbers of
665 tsRNAs subtypes. c) and d) The Bar charts show the total read counts against the read
666 lengths for the complete adapter-trimmed read set. e) and f) The Stacked Bar Charts of
667 the number of tsRNAs subtypes against tRNA iso-decoders in saline and nicotine group,
668 respectively. The X axes represents tRNA iso-decoders and the Y axes show the number
669 of all subtype tsRNAs against tRNA iso-decoders. g) and h) The Stacked Bar Charts of the
670 Frequency of Subtype against Length of the tsRNAs in saline and nicotine group,
671 respectively. The X axes represents length of tsRNAs and the Y axes show the frequency
672 of the subtype against length of tsRNAs. The color represents the subtype tsRNAs.

673

674 **Figure 4.** Validation of 8 dysregulated tsRNAs using RT-qPCR in both groups. Compared
675 with the saline group, tRF-1-T28-His-GTG-1 was significantly up-regulated in the nicotine
676 group (a). tRF-5c-Glu-CTC-1, tRF-5c-Glu-CTC-3, tRF-5c-Glu-TTC-4, tRF-5c-Gly-GCC-2-
677 M2 were all significantly down-regulated in the nicotine group(b). The data were normalized
678 using the mean \pm SEM (n = 3 per group). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

679

680 **Figure 5.** The tsRNA/mRNA network analysis. The network included the five candidate
681 tsRNAs and their predicted target mRNAs (Nodes in green color is the up-regulated tsRNA,
682 nodes in yellow color are the down-regulated tsRNAs, nodes in red color are mRNAs).

683

684 **Figure 6.** The GO annotations and pathways of target mRNAs regulated by the five
685 candidate tsRNAs. a) and b) represented the tRF-1-T28-His-GTG-1, c) and d) the tRF-5c-
686 Glu-CTC-1, e) and f) the tRF-5c-Glu-CTC-3, g) and h) the tRF-5c-Gly-GCC-2-M2, j) and k)
687 the tRF-5c-Glu-TTC-4. The bar plot shows the top 10 enrichment score values of the
688 significantly enriched GO annotations for molecular function (in blue), cellular
689 component(in green), biological processes (in light red) and the significantly enriched
690 pathway(in dark red), respectively.

691

692 **Figure 7.** Mapping of the involving signaling pathways of tRF-5c-Glu-CTC-1. a) the
693 cholinergic synapse and b) the dopaminergic synapse. Orange marked nodes are
694 associated with tRF-5c-Glu-CTC-1.